Med Review: What is the Safety and Efficacy Profile of Guselkumab in Juvenile Psoriatic Arthritis?

In this updated medication review video module, Brandon Ko, DNP, and Pediatric Chair of RhAPP, reviews the recent FDA approval of guselkumab for juvenile psoriatic arthritis (JPsA) in children ages 6 and older weighing more than 40 kg. He covers dosing, mechanism of action as an IL-23 inhibitor, and how the approval was based on extrapolated data from pediatric plaque psoriasis (PROTOSTAR) and adult psoriatic arthritis (DISCOVER-1) trials demonstrating strong efficacy and a favorable safety profile. The video also explains how guselkumab fits into the current JPsA treatment landscape alongside TNF inhibitors, abatacept, ustekinumab, secukinumab, and JAK inhibitors, with key considerations including uveitis risk, inflammatory bowel disease implications, paradoxical TNF-induced psoriasis, and safety profile. This overview provides practical guidance for pediatric rheumatology providers tailoring biologic therapy for children with juvenile psoriatic arthritis. For more rheumatology education, visit the RhAPP Content Rheum or the RhAPP ACE app.